BIT Capital’s Karyopharm Therapeutics KPTI Stock Holding History

BIT Capital’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-867	Closed	-$95.8K	–	145
2022 Q1	$95.8K	Buy	+867	New	+$108K	0.01%	105

Other funds holding KPTI

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

BIT Capital's KPTI Position: Q2 2022 in Review

BIT Capital sold out of Karyopharm Therapeutics (KPTI) in Q2 2022, closing a stake of 867 shares — an estimated $95.8K sold.

BIT Capital first reported a position in KPTI in Q1 2022 and held it in 1 quarter. The position peaked at $95.8K in Q1 2022. 149 funds tracked by Wall St. Rank hold KPTI as of Q2 2022.

BIT Capital reported no remaining Karyopharm Therapeutics position as of Q2 2022 after selling out during the quarter.
BIT Capital sold 867 Karyopharm Therapeutics shares in Q2 2022, an estimated $95.8K.
BIT Capital first reported a position in Karyopharm Therapeutics in Q1 2022 and held it in 1 quarter.
BIT Capital's Karyopharm Therapeutics position peaked at $95.8K in Q1 2022.
149 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2022.

Based on BIT Capital's 13F filing for Q2 2022, filed 12 Feb 2025.